Cereser, Biancastella http://orcid.org/0000-0003-1243-1767
Yiu, Angela
Tabassum, Neha
Del Bel Belluz, Lisa
Zagorac, Sladjana
Ancheta, Kenneth Russell Zapanta
Zhong, Rongrong
Miere, Cristian
Jeffries-Jones, Alicia Rose
Moderau, Nina
Werner, Benjamin http://orcid.org/0000-0002-6857-8699
Stebbing, Justin http://orcid.org/0000-0002-1117-6947
Article History
Received: 16 June 2021
Accepted: 3 August 2023
First Online: 6 September 2023
Competing interests
: Three authors, J.S., B.C. and N.M., serve as editors for Oncogene, part of Springer Nature Group, and J.S. is EIC. The editorial roles did not influence the research presented here. Since 2020 J.S. has sat on SABs for Vaccitech, Heat Biologics, Eli Lilly, Alveo Technologies, Pear Bio, Agenus, Equilibre Biopharmaceuticals, Graviton Bioscience Corporation, Celltrion, Volvox, Certis, Greenmantle, vTv Therapeutics, APIM Therapeutics, Onconox, IO Labs, Bryologyx, Clinical Ink, Zephyr AI and Benevolent AI, has consulted with Lansdowne partners and Vitruvian, chairs the Board of Directors for Xerion and previously BB Biotech Healthcare Trust PLC. None of these interests are relevant here. The other authors declare no competing interests.